Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens.

Accumulation of undifferentiated myeloid progenitors is a hallmark of AML, and targeting differentiation blockade represents a promising therapeutic strategy for AML. In this issue of Cell Stem Cell, Wang et al. (2021) conducted surface antigen-guided CRISPR screening and identified ZFP36L2 as a myeloid leukemia differentiation regulator and new therapeutic target.